BioVie Inc. (OTCMKTS:BIVI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02(d) Election of Directors.
On May 10, 2017, the Board of Directors of BioVie Inc. ("BioVie") elected Dr. Hari Kumar as an independent member of BioVie’s Board of Directors. Dr. Kumar is an accomplished executive in the biopharmaceutical industry, with experience in BioVie’s primary therapeutic area, liver disease, and a strong track record of building multiple successful life sciences companies.
About BioVie Inc. (OTCMKTS:BIVI)
BioVie, Inc., formerly NanoAntibiotics, Inc., is a development-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of drug therapies. The Company is focused on commercializing BIV201, which is used for the treatment of ascites due to liver cirrhosis. The Company’s therapy BIV201 is based on a drug that is approved in over 50 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites). The Company’s subsidiary is LAT Acquisition Corp. BioVie Inc. (OTCMKTS:BIVI) Recent Trading Information
BioVie Inc. (OTCMKTS:BIVI) closed its last trading session down -0.024 at 0.226 with shares trading hands.